1. Key takeaways from the quarter
Between Jul 25 and Oct 23, 2026, gene editing and cell therapy moved on four fronts: approvals went to AAV and oncolytic products, in vivo editing produced its clearest human numbers, payers built one outcomes-based template, and dealmaking shifted toward in vivo platforms. Each conclusion below is judged against Oct 24, 2026, and points to the chapter that holds the evidence.
1. The quarter's approvals were gene therapies, not editors or CAR-T, and the first in vivo CRISPR decision is still ahead. Citeline counts 49 approved gene therapies at Q3, up from 46 at Q2, which equals three US approvals: Fayuvi (standard full approval, Sept 17), Genglycos and Tudriqev (accelerated approval, Aug 6). Casgevy was extended to children aged 2 and older in July, and Vertex reported Casgevy revenue of $76.4M for Q2 2026, up 151% from $30.4M. Lonvo-z has Priority Review with a goal date of Mar 10, 2027. [Chapter 2]
2. In vivo liver editing gave the clearest numbers, and autoimmune CAR-T gave both the strongest signal and the first fatal safety event. BEAM-302 at 60 mg lifted total AAT from 5.0 to 14.4 µM, above the 11 µM threshold, in a company-reported Phase 1/2 analysis of 29 patients. Lonvo-z cut HAE attacks to 0.26 versus 2.10 per month (reported −87%) in Phase 3. In autoimmune disease, 22 of 24 patients were drug-free at 24 weeks in Erlangen's basket trial, but Novartis paused its rap-cel trials on Aug 24 after 3 deaths and no lift was reported by Oct 23. [Chapter 3]
3. Medicaid now buys sickle cell gene therapy through one CMS framework, but net prices remain unpublished. The CMS model covers 32 states, DC and Puerto Rico, representing 84% of Medicaid beneficiaries with the disease, while list prices are $2.2M for Casgevy and $3.1M for Lyfgenia. At end-2025, 64 Casgevy infusions and 115 Lyfgenia patients treated were reported, against an estimated 25,000–35,000 eligible US patients. Employers carry the exposure: million-dollar-plus claims rose 46% from 2022 to 2026 (reported via CaptivePFTN), and 2027 cost-trend surveys run 8.2% to 11.1%. [Chapter 4]
4. Capital moved to in vivo platforms on staged terms, while ex vivo assets were sold, returned or wound down. J&J's option on Sail Biomedicines pays $785M up front (22.4% of $3,505M potential, with a $2.58B option payment) for a preclinical lead. PTC won Sangamo's ST-920 at auction for $111M upfront, BMS ended a $380M Cellares agreement with 100 layoffs, and Citeline reports Q3 deal volume down 33%. [Chapter 5]
5. Delivery is proven for the liver and not elsewhere, and long-term follow-up is the thinnest evidence. Nature called Prime Medicine's PM577a the first known prime editing in a person, with one patient dosed and data due in 2027. Beyond the liver, evidence is animal, in vivo CAR-T has no mature human data, and a scoping review found 29 genome-editing trials, only 6 of them in vivo. Reported umbrella-trial designs would let variants be added under one IND, with a formal trial expected to enrol in 2027. [Chapter 6]
1.1 Therapies at a glance
| Therapy | Company | Modality | Indication | Milestone | Date | Status (Oct 24) | Source |
|---|---|---|---|---|---|---|---|
| Fayuvi | Ultragenyx | AAV9 gene therapy | MPS IIIA | FDA standard full approval | Sept 17, 2026 | Approved | — |
| Tudriqev | Replimune | Oncolytic HSV-1 | Melanoma | FDA accelerated approval; ORR 24.2% in 91 patients | Aug 6, 2026 | Approved, conditional | — |
| Casgevy | Vertex, CRISPR Therapeutics | Ex vivo CRISPR | Sickle cell disease, beta thalassemia | Label extended to ages 2+ | July 2026 | Approved | — |
| Lonvo-z | Intellia | In vivo CRISPR | Hereditary angioedema | BLA accepted, Priority Review; goal date Mar 10, 2027 | Sept 8, 2026 | Filed | — |
| BEAM-302 | Beam | Base editing | Alpha-1 antitrypsin deficiency | 60 mg: AAT 14.4 µM; pivotal cohort dosing | Sept 8, 2026 | Phase 1/2 (company-reported) | — |
| PM577a | Prime Medicine | In vivo prime editing | Wilson disease | First patient dosed | Oct 2026 | Phase 1/2 | — |
| Anito-cel | Gilead | CAR-T | Fourth-line myeloma | FDA goal date Dec 23, 2026 | Goal date | Filed | — |
| Rap-cel | Novartis | CAR-T | Autoimmune disease | 3 deaths; trials paused | Aug 24, 2026 | Hold, no lift reported | — |
| Sail lead (SAIL-0839) | Sail Biomedicines (J&J option) | In vivo CAR-T | Autoimmune disease | $2.58B option payment | Jul 29, 2026 | Preclinical | — |
2. Approvals and launches
Chapter 1 gave the quarter's headline conclusions; this chapter sets out the regulatory decisions and launch numbers behind them, judged against 2026-10-24.
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| Fayuvi (Ultragenyx; AAV9 gene therapy; MPS IIIA) | Standard full approval; 17 treated vs 27 natural-history controls | Sept 17, 2026 | Approved (FDA) | Ultragenyx; Life Science Daily |
| Tudriqev (Replimune; oncolytic HSV-1; melanoma) | Accelerated approval after a 10–3 advisory vote | Aug 6, 2026 | Approved, conditional | OncoDaily |
| Genglycos (Ultragenyx; gene therapy; GSD Ia) | Counted as a Q3 US approval | Date not stated | Approved (per Citeline) | ASGCT-Citeline |
| Casgevy, ages 2+ (Vertex and CRISPR Therapeutics; ex vivo CRISPR; SCD, TDT) | Approved 53 days after filing; about 5,500 newly eligible | July 2026, day not stated | Approved (FDA) | CRISPR Therapeutics |
| Lonvo-z (Intellia; in vivo CRISPR; HAE) | BLA accepted with Priority Review; goal date Mar 10, 2027 | Announced Sept 8, 2026 | Filed | Life Science Daily, citing Intellia |
| Anito-cel (Gilead; CAR-T; 4th-line myeloma) | FDA goal date Dec 23, 2026 | Goal date | Filed | Life Science Daily |
| Deramiocel (Capricor; allogeneic cell therapy; DMD) | Advisory committee Jul 29; goal Aug 22 or Nov 22 (sources differ) | See 2.3 | Under review; outcome not in material | FDA; Prime; Life Science Daily |
| CHMP meetings Sept 14–17 and Oct 12–15 | 12 and 6 positive opinions on new medicines; no gene or cell therapy among those named | Sept and Oct 2026 | CHMP opinions; EC decisions pending | EMA |
2.1 FDA decisions: three gene therapies, none of them CRISPR
Citeline's Q3 count (via ASGCT) puts approved gene therapies at 49, up from 46 at Q2, which equals the three Q3 US approvals: Fayuvi, Genglycos and Tudriqev. A year earlier the count was 38. The same report lists Orca Bio's Tregzi as a non-genetically modified cell therapy approved in the US, date not stated.
Fayuvi (rebisufligene etisparvovec-hopf, UX111) is the first approved treatment for Sanfilippo syndrome type A. The FDA granted standard full approval on Sept 17, 2026, and Ultragenyx received a Priority Review Voucher. According to Life Science Daily, 17 treated children were compared with 27 natural-history controls, a 23.5-point Bayley-III effect. Ultragenyx expects commercial product to ship to Qualified Treatment Centers within 30–60 days, i.e. Oct 17 to Nov 16 (Sept 17 + 30 and 60 days). Shipment status is not in the material; price is in Chapter 4.
Tudriqev (vusolimogene oderparepvec-wtpg, RP1) won accelerated approval on Aug 6, 2026, four days after its Aug 2 goal date, with nivolumab in melanoma that progressed on anti-PD-1 therapy. It followed complete response letters in July 2025 and Apr 2026. The advisory committee voted 10–3 on Jul 30. In the FDA-evaluable group of 91 patients, the response rate was 24.2% with a median duration of 14.1 months. Continued approval depends on the roughly 400-patient IGNYTE-3 trial, with data expected in 2030.
The FDA's tone shifted. OncoDaily ties the Tudriqev reversal to CBER Director Vinay Prasad leaving at the end of April and Commissioner Marty Makary weeks later. The industry body ARM counts five cell and gene therapy CRLs in 2025–2026 before stabilisation in mid-2026, and estimates up to seven approvals in 2026.
The quarter's FDA approvals were rare-disease AAV and oncolytic-virus products. No CRISPR or CAR-T product was approved; the first in vivo CRISPR decision is due Mar 10, 2027.
2.2 Casgevy: the age-2 label and launch numbers
Casgevy (exa-cel, an ex vivo CRISPR/Cas9 therapy) is approved in 39 countries. In July 2026 the FDA extended it to children aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, the first genetic therapy for that age in both diseases. CRISPR Therapeutics cites approval 53 days after filing and about 5,500 newly eligible patients (company estimate). Filings for ages 5–11 are complete in Saudi Arabia and the UK.
| Casgevy revenue | Value | Source |
|---|---|---|
| Q2 2025 | $30.4M | Vertex call (via Motley Fool) |
| Q1 2026 (implied) | about $42.9M = 76.4 ÷ 1.78 | Calculated from |
| Q2 2026 | $76.4M (+78% quarter on quarter, +151% year on year) | Vertex call (via Motley Fool); CRISPR Therapeutics |
Check: 76.4 ÷ 30.4 = 2.51, matching +151%. Vertex's release credits "increased CASGEVY infusions" outside the US and guides non-CF revenue (Casgevy and Journavx together) to at least $500M in 2026, raised full-year revenue guidance to $13.1–13.2B.
Gap: the material gives no count of patients treated, cell collections or authorised centres for Casgevy, and nothing on Zolgensma or Hemgenix launches.
2.3 Pathways, Europe and what is pending
Bespoke editing. The first three items pre-date the window. The FDA issued draft guidance on genome-editing products in February 2026, envisioning adapting an approved editor to related mutations given a plausible mechanism. On Jun 2, 2026 it published draft guidance on "Leveraging Prior Knowledge". On May 5, 2026 it issued final CMC flexibilities guidance, ending the "rule of three" batches. In the window, industry comments urged the FDA to widen the prior-knowledge guidance and link it to the plausible-mechanism framework and platform designation (AgencyIQ; date not stated). No platform designation for a gene-editing product appears in the material. Kiran Musunuru said on a podcast that the FDA cleared the Baby KJ IND in one week and has agreed to umbrella designs, with a formal trial expected to enrol in 2027 (reported).
Europe. The CHMP's September and October meetings gave 12 and 6 positive opinions, which include biosimilars and generics. Excluding those, the highlights name 8 and 4 new medicines, none a gene or cell therapy. The last ATMP step in the material is a positive CAT recommendation for Itvisma in April, before the window.
Pending US decisions.
- Deramiocel: the FDA held an advisory meeting on Jul 29. Prime lists an Aug 22 goal; Life Science Daily's Oct 9 calendar shows Nov 22. We follow the later date, but the material does not explain the change.
- Anito-cel: Dec 23, 2026.
- Lonvo-z: Mar 10, 2027; Intellia plans a first-half 2027 US launch if approved (company).
- Beam's risto-cel: BLA submission "as early as year-end 2026" (company).
- Citeline counts 11 gene therapies awaiting decisions.
3. Clinical readouts
Chapter 2 covered what regulators decided; this chapter covers the human data behind those decisions and the next filings.
3.1 Readouts at a glance
| Therapy (company, modality, indication) | Key figure | Date | Status (Oct 24, 2026) | Source |
|---|---|---|---|---|
| BEAM-302 (Beam, base editing, AATD) | 60 mg: AAT 14.4 µM vs 5.0; n=29 | Sep 8 | Phase 1/2; pivotal dosing | Beam |
| Lonvo-z (Intellia, CRISPR, HAE) | Attacks −87% vs placebo | Aug 6 | Phase 3 done; BLA accepted (reported) | Intellia |
| Nex-z (Intellia, CRISPR, ATTR) | HLA-C*05:01 in 12% | Aug 6 | Phase 3 resumed | Motley Fool |
| CTX310 (CRISPR Tx, ANGPTL3) | 0.8 mg/kg: LDL −53% | Aug 28 | Phase 1a data | Life Science Daily |
| VERVE-102 (Lilly, base editing, PCSK9) | 1.0 mg/kg: LDL −62%; n=35 | Aug 13 (print) | Phase 1; published | NEJM |
| PM577a (Prime Medicine, prime editing) | First patient dosed | Oct | Phase 1/2 | Prime Medicine |
| Zorpo-cel (Erlangen, CAR-T, autoimmune) | 22 of 24 drug-free | 2026 | Published | Nature Medicine |
| Rap-cel (Novartis, CAR-T, MG/MS) | 3 deaths; trials paused | Aug 24 | Hold, no lift reported | Rare Disease Advisor |
In vivo liver editing gave the quarter's clearest numbers. Autoimmune CAR-T gave its strongest efficacy signal and its first fatal safety event in the same weeks.
Most figures are company-reported from open-label studies. Peer-reviewed items are lonvo-z (NEJM), VERVE-102 (NEJM) and zorpo-cel.
3.2 In vivo editing: from data to filings
Beam. On Sept 8, 2026 Beam presented BEAM-302, a lipid-nanoparticle adenine base editor for AATD, at the European Respiratory Society Congress (open-label Phase 1/2; no NCT number in the material). By Aug 17, 38 patients were dosed; the analysis covers 29 (June 24 cutoff).
| 60 mg cohort, steady state (Beam) | Part A (lung) | Part B (liver) |
|---|---|---|
| Total AAT, baseline → mean | 5.0 → 14.4 µM | 4.7 → 13.5 µM |
| Z-AAT reduction | 84% | 84% |
| Corrected M-AAT share | 93% | 93% |
Both means clear the 11 µM protective threshold, at about 2.9× baseline (14.4÷5.0; 13.5÷4.7). Infusion reactions affected 41%; one Part B patient had transient Grade 3 ALT/AST elevations. Beam seeks accelerated approval on a 12-month AAT biomarker endpoint, enrolling about 50 more patients; the first pivotal patient was dosed in July. According to CRISPR Medicine News, China's YolTech reported base editor YOLT-202 in 4 patients, lifting AAT from about 5 to 20 µM through six months (date not stated).
Intellia. The Aug 6 update restated Phase 3 HAELO: 0.26 vs 2.10 attacks per month (simple ratio −87.6%; reported −87%), 62% attack-free and therapy-free vs 11%, and no serious adverse events in the lonvo-z arm. Life Science Daily puts enrolment at 80. September reports say the FDA accepted the filing with priority review; the decision date is in Chapter 2. For nex-z, Phase 3 enrolment resumed after the holds. A 600-plus-sample analysis tied the highest transaminase elevations to HLA-C*05:01, carried by 12%; HLA typing is now used, and FDA discussions continue.
Cardiovascular and prime editing. VERVE-102 (NCT06164730, funded by Verve) cut PCSK9 by 51% to 88% and LDL by 9% to 62% across six doses; 15 of 35 participants had at least one year of follow-up. CTX310 triglycerides fell 48% at 0.8 mg/kg; CRISPR Therapeutics expects Phase 1b data in H2 2026. Both datasets are small and measure blood markers, not cardiac events. CRISPR Therapeutics also started Phase 1 trials of CTX340 (refractory hypertension) and CTX460 (AATD), without data. Prime Medicine's PM577a was cleared by Medsafe (June) and the FDA (July); the first patient was dosed in October (Chosun Biz quotes "the 5th"; Nature on Oct 22 says "earlier this month", so the day is not confirmed), with data in 2027. For PM359 in chronic granulomatous disease, the company cites positive proof of concept in its first two patients and targets a BLA in the first half of 2027 (company plan). Beam expects BEAM-301 first-in-human data in 2026 and an updated risto-cel dataset by year-end.
3.3 CAR-T in autoimmune disease: efficacy up, safety questioned
Erlangen's basket trial reported drug-free control in 22 of 24 patients at 24 weeks, with no ICANS or severe CRS. Kyverna's miv-cel won RMAT in August for non-active secondary progressive MS on six Stanford patients (3 at 33 million cells, 3 at 100 million); no disability or safety data were released, and more is due in Q4 2026. A 2025 pooled analysis of 145 patients, context only, found remission in 70% of lupus patients.
The safety break came on Aug 24. Novartis paused rap-cel autoimmune trials after 3 deaths from immune effector cell-associated hemophagocytic syndrome. Bristol Myers Squibb paused zola-cel enrolment. Rare Disease Advisor says BMS called the events transient and reversible; Nature Medicine says BMS cited more ICANS in a Phase 2 trial. BMS's own statement is not in the material, so we cannot reconcile the two. Neither pause was reported lifted by Oct 23.
In vivo CAR-T has no mature data. A Sept 3 NEJM correspondence reported lentiviral in vivo CD19 CAR-T activity in neurologic autoimmune disease; HSCT Hospital India puts it at 16 patients without a control group, and the material names no sponsor. J&J's Sail option (Chapter 5) rests on a preclinical lead, SAIL-0839. Tempest and Hebei Senlang plan a trial of about 10 myasthenia gravis or MS patients in China, first dosing Q4 2026. AbelZeta's C-CAR168 won FDA clearance for a registrational Phase 2 in refractory lupus nephritis in July; according to HSCT Hospital India, a progressive MS trial of 6 to 24 patients was cleared in September.
The pauses raise the bar for autoimmune CAR-T filings, and in vivo CAR-T remains a design bet, not an evidence base.
4. Pricing and payment
Chapter 3 covered whether the new therapies work; this chapter covers who pays for the ones that do, and this quarter's evidence is that payment design, not sticker price alone, decides access.
4.1 Prices and payment terms at a glance
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| Casgevy (Vertex) | $2.2M per patient | Listed Dec 2023 | List price (WAC) | CMS; Vertex via Insurance Business |
| Lyfgenia (Genetix) | $3.1M per patient | Listed Dec 2023 | List price | CMS |
| Hemgenix (hemophilia B) | ~$3.5M | Date not stated | List, per CaptivePFTN | — |
| FAYUVI (Ultragenyx, AAV9) | $3.95M | Approved Sep 17, 2026 | Reported (note.com digest) | ; approval |
| Tudriqev (RP1) | $450,000 per course, before rebates | Approved Aug 6, 2026 | List price set | OncoDaily |
| CMS CGT Access Model | 32 states + DC + Puerto Rico | Undated page | In effect | CMS |
| Virginia Medicaid joining | Start Oct 1, 2026 | DMAS slide, Aug 2026 | Anticipated | DMAS |
| Amwins Gene Therapy Solutions | 15 therapies, up from 5 | Date not stated | Reported | Insurance Business |
| 2027 employer cost trend | 8.2%–11.1% | 2026 surveys | Estimate | — |
Every price here is a list price. No net price appears in the material. CMS says only that negotiated terms include "pricing discounts and outcomes-based rebates". Lyfgenia lists $3.1M − $2.2M = $0.9M (about 41%) above Casgevy. FAYUVI's reported price is 3.95 ÷ 2.2 ≈ 1.8x Casgevy's. Only FAYUVI and Tudriqev prices were set inside the window; for the approvals see Chapter 2.
4.2 CMS Access Model: one outcomes-based contract for Medicaid
The Cell and Gene Therapy Access Model is a voluntary, multi-year CMS model in which CMS negotiates key terms with manufacturers, then states decide whether to sign. Vertex and Genetix each signed a separate agreement with CMS. Under an outcomes-based agreement, a manufacturer refunds part of the price if the therapy does less than expected, and may add guaranteed rebates. States still pay their share, at a rebate tied to outcomes.
Medicaid now buys the sickle cell gene therapies through one CMS-negotiated, outcomes-linked framework covering 34 programs and 84% of beneficiaries with the disease; what it costs net of rebates is still unpublished.
Scale, per CMS (status: in effect):
- 32 states, DC and Puerto Rico participate, representing 84% of Medicaid beneficiaries with sickle cell disease. The state list on CMS's model page has 32 names. Mordor Intelligence says 35 programs; we follow CMS's 34.
- Medicaid covers between 50% and 60% of people with the disease.
- Start was rolling, from the first state on March 1, 2025. There are eleven performance years, ending Dec 31, 2035, with evaluation reports from 2027.
Virginia's Medicaid agency (DMAS) told stakeholders in August 2026 that it would participate from an anticipated Oct 1, 2026, carve the drug out of inpatient payment bundles so Medicaid rebates apply, and cover follow-up for up to one year. This conflicts with CMS's statement that states began between January 2025 and January 2026. We follow the state document for Virginia's go-live. The date has passed, and the material does not confirm it happened.
Not disclosed: rebate percentages, outcome thresholds, measurement windows and net prices. According to Mordor, citing CBO, sickle cell therapies could reach $1.8B a year in Medicaid spending by 2028 (estimate; the CBO document is not in the material).
4.3 Employer plans: million-dollar claims, stop-loss and co-pays
Commercial payers have insurance and financing tools but no published outcomes contracts in this material. CaptivePFTN, a captive-insurance adviser with a commercial interest, wrote on Aug 10, 2026 that Sun Life's 2026 report (70,000+ high-dollar claims, 3,300+ self-funded employers) shows million-dollar-plus claims up 46% in frequency from 2022 to 2026, with Elevidys averaging $3.6M per claim. UnitedHealthcare (Aug 6, 2026) says claims of $100,000 or more rose nearly 13% in 2025, and illustrates individual stop-loss with a $500,000 attachment point.
Illustration (our arithmetic, not a quoted case): above a $500,000 attachment, a Casgevy-priced claim leaves the carrier $2.2M − $0.5M = $1.7M, or 77%; a Lyfgenia-priced claim leaves $3.1M − $0.5M = $2.6M, or 84%.
Affordability signals for 2027 are estimates:
| Survey | 2027 employer health cost increase |
|---|---|
| Marsh | 8.2% after planned changes (11% without) |
| Business Group on Health | 9.2% |
| Aon | 9.5% (above $19,000 per employee) |
| IFEBP | 10% |
| WTW | 11.1% |
On the patient side, a May 2026 American Journal of Managed Care commentary by Shrank, Kelsay and Fendrick argues co-pays block access to one-time cures. It proposes outcomes-registry enrollment instead. The authors have commercial ties to the field, disclosed in the journal (reported by Insurance Business, Oct 19, 2026). CaptivePFTN lists carve-outs, centers of excellence, installment and "no cure, no pay" contracts as plan levers.
4.4 Access: slow uptake, and what happens when economics fail
CNBC (Oct 16, 2026) reports end-2025 uptake from company reports: 64 Casgevy infusions worldwide and 147 first cell collections (Vertex), and 115 Lyfgenia patients treated in the US with 216 collections initiated (Genetix). Collections outnumber infusions by 147 ÷ 64 ≈ 2.3 and 216 ÷ 115 ≈ 1.9, a backlog because treatment can take a year. Studies estimate 25%–35% of about 100,000 US patients qualify, or 25,000–35,000 (estimate). The 179 infused (64 + 115) are under 1% of that pool, an upper bound because Vertex's count is global.
Barriers are operational: conditioning chemotherapy that often causes infertility, weeks in hospital, and apheresis scheduling, REMS compliance and follow-up of up to 15 years. Casgevy revenue was $76.4M in Q2 2026, up 151% from $30.4M (Vertex, Aug 3, 2026). At the $2.2M list price that is about 35 courses' worth, an order of magnitude only, since revenue is global (clinical and launch detail: Chapter 2).
The failure case is hemophilia A. BioMarin withdrew Roctavian after only $36M of 2025 sales, taking a charge of about $240M; Pfizer's Beqvez was also withdrawn in 2025 (DrugPatentWatch, Sep 18, 2026). A peer-reviewed paper dated July 28, 2026 calls the Roctavian exit a failure of economic sustainability, market access and system readiness, not safety or efficacy.
Sickle cell now has a federal outcomes-based template, but employers and health systems still carry the risk and coordination burden. Without published net prices and rebate terms, outsiders cannot judge whether it lowers cost.
5. Deals and partnerships
Chapter 4 covered what payers will pay for approved gene and cell therapies. This chapter covers what buyers paid for the next generation, and which assets were sold, returned or shut down. All items are judged against 2026-10-24.
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| J&J option on Sail Biomedicines (in vivo CAR-T) | $785M initial payments (incl. $465M equity), $140M contingent, $2.58B option payment | Jul 29, 2026 | Announced; option not exercised in the material | J&J release |
| PTC buys Sangamo's ST-920 (AAV, Fabry) in bankruptcy auction | $111M upfront, up to $100M milestones | Aug 12, 2026 | Selected bidder; closing expected late Q3 or early Q4 2026, completion not confirmed | PTC (SEC EX-99.1) |
| Lilly takes Sangamo platforms and ST-506 | $50M | Aug 2026, day not stated | Reported | BioBucks |
| Janssen returns C-CAR039 to AbelZeta | 2023 upfront was $245M; return terms undisclosed | Jul 2026, day not stated | In effect | AllSci |
| BMS ends Cellares CAR-T manufacturing deal | $380M 2024 agreement; 100 layoffs | Confirmed Aug 26, 2026 | Reported (BMS spokesperson via Reuters) | CGT Review; BioPharma Dive |
| Tempest and Senlang in vivo CAR-T collaboration | Terms not disclosed | Aug 13, 2026 (release date) | Announced | Tempest |
| Abogen to Novartis (mRNA T-cell engager) | $575M upfront, up to ~$7.2B more | Oct 2, 2026 | Signed (tracker) | CDMO Hub |
| China draft ban on foreign purchase of cell and gene therapy platforms | Comments until Nov 15 | Oct 16, 2026 | Proposed, not in effect | Fierce Biotech |
J&J paid 22% of Sail's potential value up front and kept the rest as an option. Elsewhere in the quarter, a BLA-stage gene therapy cleared a bankruptcy auction at $111M upfront, and an ex vivo CAR-T and its manufacturer lost their pharma partners.
5.1 J&J and Sail: a staged bet on in vivo CAR-T
On Jul 29, 2026 Johnson & Johnson announced a collaboration, an equity investment and an exclusive option to acquire Sail Biomedicines. The deal is subject to regulatory approvals and other conditions.
| Component (J&J release) | Amount | Share of total |
|---|---|---|
| Initial payments, incl. $465M equity | $785M | 22.4% |
| Contingent development milestones | $140M | 4.0% |
| Option payment if exercised | $2,580M | 73.6% |
| Total potential | $3,505M | 100% |
All three components come from J&J. The total is 785 + 140 + 2,580 = 3,505, and AllSci's "more than $3.5 billion" agrees. The other $320M of the initial payments (785 − 465) is not itemised. AllSci splits the $785M differently, but its parts do not add up, so we follow J&J. J&J expects exercise to dilute adjusted EPS by about $0.18 in 2026 and $1.28 in 2027.
Sources disagree on the lead asset. J&J names none. CGTlive and pharmaphorum call it SAIL-0839, which targets CD4 and CD8 cells for autoimmune disease. AllSci calls it SAIL-0804, an anti-CD19 candidate moving toward IND-enabling studies. We follow SAIL-0839 as the majority view. Under either name it is preclinical, with no human data.
Earlier in vivo deals are context only: Lilly–Orna $2.4B (Feb 2026), AbbVie–Capstan $2.1B and BMS–Orbital $1.5B (both 2025). For Lilly's April 2026 Kelonia deal, CGTlive reports $3.25B upfront, while pharmaphorum and AllSci say "up to $7 billion". We read this as an upfront inside a larger headline, though no primary source is in the material. On that reading Kelonia paid 3.25 ÷ 7 ≈ 46% up front against Sail's 22% (estimate), so J&J committed less before deciding.
Janssen also returned global rights to AbelZeta's anti-CD19/CD20 CAR-T C-CAR039 in July 2026, unwinding a 2023 deal that paid $245M upfront for it and a second asset. J&J has not linked the return to Sail, and the second asset's status is unclear.
5.2 Auctions, retreats and China
Sangamo. On Aug 12, 2026 PTC Therapeutics said it won the bankruptcy auction for ST-920, an AAV gene therapy for Fabry disease, paying $111M upfront plus up to $100M on regulatory approvals, a maximum of 111 + 100 = $211M. According to BioBucks, the auction cleared at $163.55M cash, beating stalking horse Astellas, and Lilly paid $50M for Sangamo's capsid, zinc finger and MINT platforms and the prion program ST-506. PTC plus Lilly is 111 + 50 = $161M, so $2.55M of the total is not itemised.
Retreats. Cellares, which makes cell therapies for others, is cutting 100 jobs after a large customer ended its contract, with terminations due by Oct 20 (so in effect). Endpoints and Reuters confirmed on Aug 26 that the customer was BMS. A BMS spokesperson said the Cell Shuttle could not meet commercial-scale needs for Breyanzi, and Cellares disagrees. Fierce's layoff tracker adds Arsenal Biosciences (99 cuts, Aug 31, pivot to in vivo CAR-T), TScan (75% cut, Sep 2, in vivo focus) and Caribou Biosciences (pipeline halted, Oct 6, seeking alternatives). The cuts mostly point toward in vivo work.
China. CDMO Hub counted 22 signed China-linked licensing deals between Aug 19 and Oct 14, worth about US$24B in potential value, with more than US$1.5B upfront from the seven deals that state it. Few are cell or gene therapy. Abogen's mRNA that makes a CD19×CD3 T-cell engager went to Novartis for US$575M upfront plus about US$7.2B in milestones, so 575 + 7,200 ≈ US$7.78B and upfront is about 7%. Tempest's Aug 13 release says it signed a development collaboration with Hebei Senlang on in vivo CAR-T, including CD7-targeted TPST-4003, with a trial in about 10 patients with myasthenia gravis or multiple sclerosis and first dosing expected in Q4 2026. CDMO Hub lists the same deal as an option with terms "need further clarification". We follow Tempest for the structure. Tempest held only $0.8M cash at Jun 30.
On Oct 16, 2026 Fierce reported a Chinese draft export-control update that would bar foreign acquisitions of proprietary cell and gene therapy and siRNA platforms. Out-licensing and outsourced research or manufacturing are excluded, a Ministry of Commerce spokesperson said. Comments run to Nov 15 and the rule is only a proposal. AstraZeneca's roughly $1B Gracell purchase would likely not have been possible under it, but option and licence structures such as Tempest's are untouched.
5.3 Financing: fewer, larger cheques
Citeline's Q3 2026 landscape report (Oct 2026) says transaction volume fell 33% from Q2, mainly in alliances and financings, with eight M&As. The largest was Repligen's $1.5B purchase of cell bioprocessing company BioLife Solutions.
| Citeline metric | Q2 2026 | Q3 2026 |
|---|---|---|
| Transactions | 118 | ~79 (estimate: 118 × 0.67) |
| Seed and Series A rounds | 20 | 14 |
| Seed and Series A value | $500.4M | $387.9M |
Q3 seed and Series A value is 387.9 ÷ 500.4 ≈ 78% of Q2, down 22%, while the count is down 30% (14 ÷ 20). According to New Market Pitch, Encoded Therapeutics raised $275M (AAV, Sep 2026) and BrainChild Bio $116M (CAR-T for CNS tumours, Sep 2026). Obsidian raised a $350M PIPE (Jul 2026) and Immatics a $173M follow-on (Aug 2026). Editas reported on Aug 5 that its May offering raised $125.0M gross, with cash of $211.6M at Jun 30 and runway into H2 2028. In July 2026 Prime Medicine said an arbitration tribunal found its alpha-1 program PM647 within its field under the 2019 Beam collaboration, with no breach and no damages (company-reported).
For developers, the market now funds in vivo platforms on staged terms, while late-stage or ex vivo assets without that story are sold, returned or wound down. Dated watch points: PTC's closing (expected late Q3 or early Q4 2026, not confirmed in the material), China's Nov 15 comment deadline, and any J&J exercise decision (no date stated).
6. Technology progress
Chapter 5 followed the money into in vivo platforms; this chapter checks what the technology has actually shown, and in which species.
6.1 Evidence scorecard: humans versus animals
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| PM577a, in vivo prime editing (Wilson disease) | First patient dosed; data 2027 | Oct 2026 | Phase 1/2, company-reported | Prime Medicine; Nature |
| PM359, ex vivo prime editing (CGD) | 2 patients; BLA targeted 1H 2027 | Aug 6, 2026 | Phase 1/2, company-reported | Prime Medicine |
| VERVE-102, in vivo base editor (NCT06164730) | 35 participants; 15 followed 1 year+ | Aug 13, 2026 | Phase 1, published | NEJM |
| TPST-4003, in vivo CAR-T | About 10 patients planned | Aug 13, 2026 | Announced, not dosed | Tempest |
| Sail lead, in vivo CAR-T | 50-80% T-cell transfection | Jul 29, 2026 | Preclinical | AllSci |
| OptiPrime, pegRNA design | 40% cortex correction, mice | Aug 12, 2026 | Preclinical | Broad Institute |
Liver LNP delivery has human datasets for several editors, prime editing in the body has one dosed patient, in vivo CAR-T has dosing plans and one correspondence, and long-term follow-up is the thinnest layer of evidence.
6.2 Delivery: liver LNP is a platform, in vivo CAR-T is still three bets
Liver. Prime editing reached the body on a liver LNP. Nature called PM577a "the first known instance" of prime editing in a person; no in vivo editing therapy is approved yet (see Chapter 2). Prime Medicine said the first patient was treated "earlier this month" (Nature, Oct 22) after a New Zealand CTA (June 2026) and FDA IND (July 2026); the trial starts in stable adults and tests safety, dose and copper excretion. H1069Q accounts for about 30-50% of ATP7B mutations in the US and Europe, according to the company via Chosun Biz; an East Asian variant (R778L) programme is preclinical. The same universal liver LNP underpins PM647 for alpha-1 antitrypsin deficiency. CRISPR Medicine News (Sep 25) reports FDA clearance of the PM647 Phase 1/2. CRISPR Therapeutics runs CTX340 and CTX460 on its own liver LNP; both were in Phase 1 by Aug 3, 2026. VERVE-102 uses a GalNAc-bearing LNP. Chemistry still improves, but in animals: fully modified pegRNAs raised mouse liver editing to 67% and edited Pcsk9 nearly 80 times more efficiently than end-modified guides (preclinical, via CRISPR Medicine News).
Beyond the liver, evidence is animal. A Huntington's base editor was delivered by split-intein AAV to rodent striatum. Reviews list endosomal escape, extrahepatic targeting and the "PEG dilemma" as open LNP problems (Jun 8, 2026), and call delivery the core bottleneck (ACS Nano, Oct 6, 2026).
In vivo CAR-T. Three vectors compete. Lentiviral: IASO Biotechnology's CD20 candidate IASO208 (third-generation lentiviral vector, InTelliCAR) reportedly received an FDA IND in the second half of September, per a Japanese industry newsletter. mRNA/LNP: Tempest's TPST-4003 pairs CD7-targeted delivery with a CD19/BCMA CAR. Circular RNA: Sail combines eRNA with targeted LNP, and its lead is preclinical; RiboX's RXIM002 reportedly cleared a US IND and CREATE's CRT-402 Australian ethics approval, both from the newsletter's first-half August issue. Two conflicts. The newsletter says Tempest holds a lentiviral candidate already in Phase 1, but Tempest's own Aug 13 release says mRNA/LNP with first dosing expected in Q4 2026; we follow Tempest. Sail's lead is "SAIL-0839" in CGTlive and "SAIL-0804" in AllSci; J&J's release names neither.
The only human in vivo CAR-T result in this material is a Sept 3, 2026 NEJM correspondence on lentiviral CD19 CAR-T in MS and NMOSD, known only through an opinion piece (see Chapter 3). A review (Immunity & Inflammation, Aug 31, 2026) says LNP-mRNA and targeted lentiviral systems both transduce T cells efficiently in primates and that early trials show "promising safety and preliminary efficacy"; it flags short mRNA persistence and repeat-dosing immunogenicity. The manufacturing case is stated, not measured: Nature says in vivo products "might be much cheaper and faster", with no cost data.
6.3 Personalised editing and safety: the bottleneck moves to evidence
Bespoke and umbrella. The 2025 neonatal CPS1 therapy (kayjayguran abengcemeran, "k-abe") was an in vivo N-of-1 base editor. According to Kiran Musunuru on a podcast, relayed by BigGo (date not stated), the FDA cleared the IND in one week, design to infusion took six months, and the FDA has agreed to umbrella designs that bundle variants, even seven urea cycle disorders, in master protocols, with a formal trial expected to enrol in 2027. That is a researcher's account (reported), not an FDA document. A Danaher blog (Jun 24, 2026, pre-window) describes the model: one IND, shared editor and delivery, variants added by amendment. At ASGCT 2026 Musunuru posed adding a variant on cellular on- and off-target data alone, without new animal toxicology (a proposal, not an accepted rule); cGMP, process validation and analytics are still required before dosing. The FDA's draft guidance on prior knowledge (Jun 2, 2026) sits in Chapter 2.
Off-target and follow-up. Tracking-seq2 found that genomic variation drives off-target differences between individuals, so safety assessment may need to be personalised. Broken String Biosciences, which sells the INDUCE-seq assay, argues for genome-wide, cell-based screening early in discovery (vendor view). The scoping review found 29 trials: 23 used CRISPR-Cas9 (23 / 29 = 79%), all were Phase I/II, 6 / 29 = 21% were in vivo, and later-timepoint outcomes were reported less often than 3- and 6-month results. A UCL workflow reached 61% knock-in in more than 100 million CD34+ cells, but the corrected fraction fell after transplantation in mice and rare donor-specific alterations were seen. In the VERVE-102 paper, adverse events were mild-to-moderate infusion reactions, transient ALT elevations and one aspiration pneumonitis.
Judgement. Delivery is proven for the liver and not elsewhere. First 2027 data from PM577a and TPST-4003 will show whether it generalises; follow-up beyond one year is the gap.
7. Outlook and what to watch
Chapters 2–6 covered approvals, readouts, prices, deals and technology. This chapter turns them into what changed for each reader, the decisions due next, and a dated watch-list. It uses only facts from those chapters, is not medical or investment advice, and judges every date against Oct 24, 2026.
7.1 What changed, and what it means by reader
| Reader | What changed | Implication | Evidence |
|---|---|---|---|
| Patients and treatment centres | Casgevy extended to ages 2+ (about 5,500 newly eligible, company estimate); Fayuvi approved Sept 17 with shipment to Qualified Treatment Centers expected within 30–60 days | Capacity, not eligibility, is the limit: 179 patients infused by end-2025 is under 1% of an estimated 25,000–35,000 eligible US patients | — |
| Developers | FDA approvals went to AAV and oncolytic products; accelerated approval for Tudriqev rests on IGNYTE-3 data expected in 2030; autoimmune CAR-T trials were paused after 3 deaths | Confirmatory evidence and safety follow-up now decide timelines; in vivo CAR-T has dosing plans but no mature human data | — |
| Payers and employers | One CMS outcomes-based model covers 32 states, DC and Puerto Rico (84% of Medicaid beneficiaries with sickle cell disease); million-dollar claims up 46% in self-funded plans (reported) | Medicaid has a template but net prices are unpublished; employers still carry the risk, and a $500,000 stop-loss leaves a Casgevy-priced claim 77% with the carrier (our arithmetic) | — |
| Dealmakers and funders | J&J paid $785M of $3,505M potential value up front for a preclinical in vivo CAR-T lead; Q3 deal volume fell 33% | Staged terms favour in vivo platforms; ex vivo assets without that story were returned or wound down | — |
| Gene-editing teams | Prime editing reached a person; FDA drafted guidance on prior knowledge (Jun 2) and umbrella designs are reported | Liver delivery is the proven route; broader platform rules are still drafts | — |
The quarter proved delivery and payment design for a few liver and blood diseases, not yet for editing at scale: the next evidence is regulatory decisions in 2026–2027 and follow-up beyond one year.
7.2 Decisions and data to watch, by therapy
Next regulatory decisions. Gilead's anito-cel has an FDA goal date of Dec 23, 2026. Capricor's deramiocel is listed for Nov 22 in Life Science Daily's Oct 9 calendar, while an earlier source gave Aug 22; we follow the later date, and no outcome is in the material. Intellia's lonvo-z, the first in vivo CRISPR therapy to reach a decision, is due Mar 10, 2027, with a first-half 2027 US launch planned if approved (company). Citeline counts 11 gene therapies awaiting decisions.
Company-guided data and filings. Beam plans a BLA for risto-cel as early as year-end 2026 and an updated dataset by year-end. CRISPR Therapeutics expects CTX310 Phase 1b data in H2 2026. Kyverna expects more miv-cel data in Q4 2026. Tempest and Senlang expect first dosing in about 10 patients in Q4 2026. Prime Medicine targets a PM359 BLA in the first half of 2027 and PM577a data in 2027.
Unresolved items. The rap-cel and zola-cel pauses were not reported lifted by Oct 23. PTC's closing of the ST-920 purchase was expected in late Q3 or early Q4 2026, and completion is not confirmed in the material. Virginia's Medicaid start was anticipated for Oct 1 and is not confirmed. No exercise decision date is stated for J&J's Sail option.
Evidence gaps that limit any forecast. No net price or rebate term is published for the CMS model or any therapy in the material, so cost cannot be judged. The material has no Casgevy patient count after the end-2025 figure of 64 infusions, and nothing on Zolgensma or Hemgenix launches. The scoping review found 29 genome-editing trials, all Phase I/II, with later-timepoint outcomes reported less often than 3- and 6-month results. Until these gaps close, treat the dated items below as the checkable milestones and the rest as direction, not outcome.
7.3 Key dates
Dates already past on Oct 24, 2026 are marked "In effect".
| Date | Event | State on Oct 24, 2026 | Source |
|---|---|---|---|
| Jul 29, 2026 | J&J announces option to acquire Sail Biomedicines | In effect | J&J |
| Aug 6, 2026 | FDA accelerated approval of Tudriqev | In effect | OncoDaily |
| Aug 24, 2026 | Novartis pauses rap-cel autoimmune trials; no lift reported | In effect | Rare Disease Advisor |
| Sept 8, 2026 | Lonvo-z BLA accepted with Priority Review | In effect | Life Science Daily |
| Sept 17, 2026 | FDA standard full approval of Fayuvi | In effect | Ultragenyx |
| Oct 1, 2026 | Virginia Medicaid start in CMS model (anticipated; not confirmed) | In effect | DMAS |
| Oct 20, 2026 | Cellares layoffs due after BMS ended its agreement | In effect | BioPharma Dive |
| Nov 15, 2026 | China draft rule on foreign purchase of cell and gene therapy platforms: comments close | Upcoming | Fierce Biotech |
| Nov 22, 2026 | Deramiocel FDA goal date (Aug 22 in an earlier source) | Upcoming | Life Science Daily; Prime |
| Dec 23, 2026 | Anito-cel FDA goal date | Upcoming | Life Science Daily |
| Q4 2026 | Tempest and Senlang first dosing of in vivo CAR-T | Upcoming | Tempest |
| Year-end 2026 | Beam risto-cel BLA submission as early as this date | Upcoming | Beam |
| Mar 10, 2027 | Lonvo-z FDA goal date | Upcoming | Life Science Daily |
| 2030 | Tudriqev IGNYTE-3 confirmatory data expected | Upcoming | OncoDaily |
8. References
This document draws on the following 77 sources, listed in the order they are first cited.
- Gene, Cell, & RNATherapy Landscape Report — asgct.org
- Landscape Report — asgct.org
- Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)—Ultragenyx Pharmaceutical Inc. — ir.ultragenyx.com
- Third Time's the Charm: FDA Approves Replimune's Tudriqev (RP1) for Advanced Melanoma - OncoDaily — oncodaily.com
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | CRISPR Therapeutics — ir.crisprtx.com
- Vertex (VRTX) Q2 2026 Earnings Call Transcript | The Motley Fool — fool.com
- In Vivo Gene Editing: What the Clinical Data Now Shows — lifesciencedaily.news
- Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | Beam Therapeutics — investors.beamtx.com
- Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics — ir.intelliatx.com
- A reality check for autoimmune CAR T cells | Nature Medicine — nature.com
- Developers Pause CAR T-Cell Trials in MG, MS, Other Conditions — rarediseaseadvisor.com
- CGT Access Model Frequently Asked Questions | CMS — cms.gov
- Sickle cell gene therapies offer new hope, accessing them is hard — cnbc.com
- Gene and Cell Therapy Claimant Exposure in Self-Funded Health Plans for 2026 | CaptivePFTN — captivepftn.com
- 2027 Health Benefits Renewal: An 8% Cost Increase Playbook — hotalinginsurance.com
- Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset — jnj.com
- J&J Secures $2.58B Option to Acquire Sail Biomedicines | CGTlive® — cgtlive.com
- EX-99.1 — sec.gov
- Cellares, a cell therapy manufacturing specialist, to lay off 100 employees | BioPharma Dive — biopharmadive.com
- A first for CRISPR: powerful prime editing alters DNA directly in the human body | Nature — nature.com
- Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates - Prime Medicine, Inc. — investors.primemedicine.com
- A scoping review of gene editing in clinical trials: identifying aspects of trial design to accelerate clinical adoption — sciencedirect.com
- In Vivo CAR-T for CNS Autoimmune Disease Looks Promising. The Trial Design Problem Is Hiding in Plain Sight. — clinicaltrialvanguard.com
- Kiran Musunuru Says FDA Cleared Baby KJ's Personalized CRISPR Therapy in One Week — BigGo Finance — finance.biggo.com
- Beam Therapeutics Presents Updated Clinical Data from the — globenewswire.com
- FDA drug approval decisions: the autumn 2026 calendar | Life Science Daily News — lifesciencedaily.news
- Cellular, Tissue, and Gene Therapies Advisory Committee ... — fda.gov
- FDA Decisions Expected: August 2026 - Prime Therapeutics - Portal — primetherapeutics.com
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026 | European Medicines Agency (EMA) — ema.europa.eu
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026 | European Medicines Agency (EMA) — ema.europa.eu
- Reasons to Believe: — alliancerm.org
- VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised — finance.yahoo.com
- Vertex Pharmaceuticals | Vertex Reports Second Quarter 2026 Financial Results — investors.vrtx.com
- AgencyIQ — Eager to leverage prior knowledge, industry pushes FDA to broaden draft guidance’s scope - Friends of Cancer Research — friendsofcancerresearch.org
- Analyzing FDA’s Flexible Framework for Cell and Gene Therapy CMC — bioprocessintl.com
- Gene Therapy 2026: New Approvals and Their Significance — aristo-group.com
- Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Beam Therapeutics — investors.beamtx.com
- Intellia (NTLA) Q2 2026 Earnings Call Transcript | The Motley Fool — fool.com
- In Vivo Base Editing of PCSK9 with VERVE-102 for ... — natap.org
- News: CMN Weekly (25 September 2026) - Your Weekly CRISPR Medicine News - CRISPR Medicine — crisprmedicinenews.com
- Intellia Therapeutics Q2 Earnings Call Highlights — finance.yahoo.com
- Prime editing enters first in-body trial to fix Wilson disease mutations - CHOSUNBIZ — biz.chosun.com
- Beam Therapeutics Reports Second Quarter 2026 ... — investors.beamtx.com
- Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis | CGTlive® — cgtlive.com
- CAR T Cell Therapy for MS or HSCT: How They Compare — hsctindia.com
- Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update | Tempest Therapeutics — ir.tempesttx.com
- J&J hands C-CAR039 back to AbelZeta amid pivot toward in vivo CAR-T — allsci.com
- Co-pays are blocking access to million-dollar cures, researchers say | Insurance Business — insurancebusinessmag.com
- Gene Therapy and Cell Therapy Industry Trends: Second Half of September 2026｜r-nozaw — note.com
- DMAS Cell Gene Therapy Access Model Implementation ... — dmas.virginia.gov
- CGT (Cell and Gene Therapy Access) Model | CMS — cms.gov
- Gene Therapy Market Size 2026-2031 Forecast Report — mordorintelligence.com
- Stop loss insurance: Providing greater financial protection | Brokers | UnitedHealthcare — uhc.com
- The hidden coordination burden behind cell and gene therapy access | HSES 2026 | Managed Healthcare Executive — managedhealthcareexecutive.com
- No Generic Waiting in the Wings: Why the Gene Therapy Patent Cliff Isn’t a Small-Molecule Patent Cliff - DrugPatentWatch – Transform Data into Market Domination — drugpatentwatch.com
- Roctavian withdrawal: exploring the gap between innovation and healthcare system readiness in hemophilia A gene therapy — pmc.ncbi.nlm.nih.gov
- Biotech M&A Tracker 2026 — Updated Daily | BioBucks — biobucks.co
- Cellares unveils layoffs following partnership loss | Cellgenetherapyreview.com — cellgenetherapyreview.com
- China Drug Licensing Tracker: Edition 1 | CDMO Hub — cdmohub.ai
- China to ban foreign acquisitions of key biotech platforms — fiercebiotech.com
- J&J secures option to acquire Sail in USD 3.5 billion in vivo CAR-T alliance — allsci.com
- J&J takes $2.58bn option to buy in vivo CAR-T firm Sail | pharmaphorum — pharmaphorum.com
- Fierce Biotech Layoff Tracker 2026 — fiercebiotech.com
- Biotech BD&L Tracker 2026: 157 Licensing & Partnering Deals — biobucks.co
- Biotechnology Funding Tracker (1,094 deals) – New Market Pitch — newmarketpitch.com
- Top Cell Therapy Startups by Fundraising (2026) – New Market Pitch — newmarketpitch.com
- Editas Medicine Announces Second Quarter 2026 Results and Business Updates | Editas Medicine — ir.editasmedicine.com
- AI model streamlines prime editing | Broad Institute — broadinstitute.org
- In vivo CRISPR base editing for treatment of Huntington’s disease | Nature Biomedical Engineering — nature.com
- Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles — pmc.ncbi.nlm.nih.gov
- Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes | ACS Nano | ACS Publications — pubs.acs.org
- Gene Therapy and Cell Therapy Industry Trends: First Half of August 2026｜r-nozaw — note.com
- In vivo CAR-T therapy transforms customized treatments into universal medicines — news-medical.net
- On-target and Off-target Activities of CRISPR Therapeutics Across Scales — pmc.ncbi.nlm.nih.gov
- Umbrella Trials for Scalable Gene Editing Therapies | Danaher Life Sciences — lifesciences.danaher.com
- Ultra-sensitive profiling of CRISPR-Cas off-target effects with Tracking-seq2 | Nature Communications — nature.com
- The Off-Target Problem the Gene Editing Industry Can No Longer Afford to Ignore — Broken String Biosciences — brokenstringbio.com